Two-Year Outcomes of Daily and Twice-Weekly Teriparatide Treatment in Postmenopausal Women with Severe Osteoporosis: A Randomized Non-Blinded Prospective Study.

Q2 Medicine Journal of Bone Metabolism Pub Date : 2024-05-01 Epub Date: 2024-05-31 DOI:10.11005/jbm.2024.31.2.162
Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ken Okazaki
{"title":"Two-Year Outcomes of Daily and Twice-Weekly Teriparatide Treatment in Postmenopausal Women with Severe Osteoporosis: A Randomized Non-Blinded Prospective Study.","authors":"Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ken Okazaki","doi":"10.11005/jbm.2024.31.2.162","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The long-term effects of daily teriparatide (D-TPTD) and twice-weekly TPTD (W-TPTD) injections are compared among postmenopausal women with severe osteoporosis.</p><p><strong>Methods: </strong>A total of 102 patients were enrolled and randomly allocated into two groups for the administration of either D-TPTD or W-TPTD. Treatment efficacy was measured as the percentage change in bone mineral density (ΔBMD) from baseline in the lumbar spine, total hip, and femoral neck. The findings were compared between the two groups.</p><p><strong>Results: </strong>At 24 months after treatment, the persistence rates and medication possession ratios in the D-TPTD and W-TPTD groups were 68.6% and 56.9%, and 87.8% and 92.0%, respectively. The ΔBMD in the lumbar spine, total hip, and femoral neck were 15.6%±10.2%, 5.3%± 6.3%, and 5.5%±6.2%, respectively, in the D-TPTD group; and 9.5%±7.9%, 2.3%±6.2%, and 3.1%±7.4%, respectively, in the W-TPTD group following 24 months of treatment. The ΔBMD of the lumbar spine (p=0.008) at 24 months and total hip (p=0.024) at 18 months differed significantly between the two groups.</p><p><strong>Conclusions: </strong>D-TPTD administration resulted in a significantly higher BMD in the lumbar spine and total hip, supporting this therapeutic regimen for postmenopausal women with severe osteoporosis.</p>","PeriodicalId":15070,"journal":{"name":"Journal of Bone Metabolism","volume":"31 2","pages":"162-168"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11184152/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11005/jbm.2024.31.2.162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The long-term effects of daily teriparatide (D-TPTD) and twice-weekly TPTD (W-TPTD) injections are compared among postmenopausal women with severe osteoporosis.

Methods: A total of 102 patients were enrolled and randomly allocated into two groups for the administration of either D-TPTD or W-TPTD. Treatment efficacy was measured as the percentage change in bone mineral density (ΔBMD) from baseline in the lumbar spine, total hip, and femoral neck. The findings were compared between the two groups.

Results: At 24 months after treatment, the persistence rates and medication possession ratios in the D-TPTD and W-TPTD groups were 68.6% and 56.9%, and 87.8% and 92.0%, respectively. The ΔBMD in the lumbar spine, total hip, and femoral neck were 15.6%±10.2%, 5.3%± 6.3%, and 5.5%±6.2%, respectively, in the D-TPTD group; and 9.5%±7.9%, 2.3%±6.2%, and 3.1%±7.4%, respectively, in the W-TPTD group following 24 months of treatment. The ΔBMD of the lumbar spine (p=0.008) at 24 months and total hip (p=0.024) at 18 months differed significantly between the two groups.

Conclusions: D-TPTD administration resulted in a significantly higher BMD in the lumbar spine and total hip, supporting this therapeutic regimen for postmenopausal women with severe osteoporosis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
严重骨质疏松症绝经后妇女接受每日和每周两次特立帕肽治疗的两年结果:一项随机非盲法前瞻性研究。
背景:比较了每天注射特立帕肽(D-TPTD)和每周注射两次特立帕肽(W-TPTD)对绝经后严重骨质疏松症妇女的长期影响:比较每天注射特立帕肽(D-TPTD)和每周注射两次特立帕肽(W-TPTD)对绝经后严重骨质疏松症妇女的长期影响:共招募了 102 名患者,并将其随机分配到两组,分别注射 D-TPTD 或 W-TPTD。治疗效果以腰椎、全髋和股骨颈的骨矿物质密度(ΔBMD)与基线相比的百分比变化来衡量。两组结果进行了比较:治疗 24 个月后,D-TPTD 组和 W-TPTD 组的持续率和药物持有率分别为 68.6% 和 56.9%,以及 87.8% 和 92.0%。治疗 24 个月后,D-TPTD 组的腰椎、全髋和股骨颈ΔBMD 分别为 15.6%±10.2%、5.3%±6.3% 和 5.5%±6.2%;W-TPTD 组的腰椎、全髋和股骨颈ΔBMD 分别为 9.5%±7.9%、2.3%±6.2% 和 3.1%±7.4%。24个月时腰椎的ΔBMD(p=0.008)和18个月时全髋的ΔBMD(p=0.024)在两组之间存在显著差异:结论:服用 D-TPTD 后,腰椎和全髋的 BMD 明显增加,支持对绝经后严重骨质疏松症妇女采用这种治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Bone Metabolism
Journal of Bone Metabolism Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
3.70
自引率
0.00%
发文量
23
期刊最新文献
Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia. Zoledronate Therapy in Osteogenesis Imperfecta: Perspectives in Indonesia Tertiary Hospital. Age- and Sex-Related Volumetric Density Differences in Trabecular and Cortical Bone of the Proximal Femur in Healthy Population. Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease. Discriminatory Accuracy of Fracture Risk Assessment Tool in Asian Populations: A Systematic Review and Meta-Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1